Evidence map›Paper›PMID 26995298›Full record

Trial reportThe lancet. Psychiatry2016

Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.

Carrie Shilyansky, Leanne M Williams, Anett Gyurak, Anthony Harris, Timothy Usherwood, Amit Etkin

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The lancet. Psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00693849 (International Study to Predict Optimised Treatment - in Depression), which is not on this map. Cited by 123 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 6 pooled it
24.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00693849 phase4unknown statusnot on this map

International Study to Predict Optimised Treatment - in Depression

TypeinterventionalSponsorBRC Operations Pty. Ltd.Ran2008 to 2019Enrolled2,688ConditionsMajor Depressive DisorderArmsEscitalopram, Sertraline, Venlafaxine-XR
3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 6 syntheses or guidelines pooled it, 240 citations in OpenAlex.

  1. Augmentation Therapy With Serotonin 5-HTNeuropsychopharmacology reports · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. 5-HTBiological psychiatry. Cognitive neuroscience and neuroimaging · 2023
    Trial
  13. Trial
  14. Trial
  15. Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2020
    Trial
  20. Trial

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Carrie ShilyanskyDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Leanne M WilliamsDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Anett GyurakDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Anthony HarrisBrain Dynamics Center, University of Sydney Medical School and Westmead Millennium Institute for Medical Research at Westmead Hospital, Sydney, NSW, Australia.
Timothy UsherwoodDepartment of General Practice, Sydney Medical School, Westmead, University of Sydney, Sydney, NSW, Australia.
Amit EtkinDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. Electronic address: amitetkin@stanford.edu.
Stanford University · USThe University of Sydney · AUVA Palo Alto Health Care System · USWestmead Institute for Medical Research · AU

Funding

A BIOBEHAVIORAL RESEARCH TRAINING PROGRAMT32MH019938 · NIMH · STANFORD UNIVERSITY · PI Corey J Keller, RACHEL MANBER · 1994 to 2026
$9.4M
NIMH NIH HHS T32 MH019938
6 · The paper itself

Abstract

backgroundAntidepressant treatment failure is a common problem worldwide. In this study, we assess whether or not an important aspect of depression, cognitive impairment, is untreated by antidepressants by studying the effect of acute antidepressant treatment on a range of cognitive domains.

methodsIn this randomised longitudinal study, which is part of the International Study to Predict Optimized Treatment in Depression (iSPOT-D) trial, we assessed the effects of acute antidepressant treatment in a large patient population, across clinical remission outcomes, on a range of cognitive domains: attention, response inhibition, executive function during visuospatial navigation, cognitive flexibility, verbal memory, working memory, decision speed, information processing speed, and psychomotor response speed. We enrolled patients from primary or specialty care clinics in a multicentre, international, open-label, randomised, prospective trial. Eligible patients (aged 18-65 years) were previously untreated or were willing to undergo a 1-week medication washout before the study start, and could not have had inadequate response to study medications in the past. We enrolled a large population of medication-free (ie, untreated) outpatients in a depressive episode and assessed them for cognitive function at enrolment (pre-treatment), and again after 8 weeks of treatment with one of three antidepressant drugs (escitalopram, sertraline, or venlafaxine extended-release). Patients were randomly assigned (1:1:1) to one of the three antidepressants using a blocked randomisation procedure (block size of 12). As a comparison group, we also simultaneously enrolled matched healthy participants. Healthy participants received no medication or intervention, but were assessed for change in cognitive and clinical measures during the same interval and testing protocol. Therefore, this group acts as a test-retest control for the primary outcome measure examined in this study, change in cognitive measures over 8 weeks of treatment in depressed patients. This study is registered with ClinicalTrials.gov, number NCT00693849.

findingsBetween Dec 8, 2008, and Sept 30, 2011, we enrolled 1008 eligible people into the study. Impairment in five domains-attention, response inhibition, verbal memory, decision speed, and information processing-showed no relative improvement with acute treatment (controlling for time or repeated testing), irrespective of antidepressant treatment group, even in patients whose depression remitted acutely according to clinical measures. Broader cognitive impairment was associated with greater illness chronicity (earlier illness onset) but not with symptom severity or previous antidepressant failures.

interpretationDepression is associated with impairments in higher-order cognitive functions and information processing, which persist independently of clinical symptom change with treatment. We recorded no difference between the three antidepressants tested, with none showing efficacy for these impairments. Although the 8-week treatment period limits interpretation to acute treatment effects, it does highlight cognitive impairment as an untargeted contributor to incomplete treatment success.

fundingBrain Resource Company Operations Pty Ltd and NIH.

Indexed as

AdolescentAdultAgedAntidepressive AgentsCitalopramCognitive DysfunctionDepressionFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesSertralineTreatment OutcomeVenlafaxine HydrochlorideAntidepressive AgentsCitalopramSertralineVenlafaxine Hydrochloride

Identifiers

PMID26995298
PMCPMC4860142
OpenAlexW2301371005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.